SMS Pharmaceuticals Recommends 40% Final Dividend; Approves Financial Results & Office Shift
SMS Pharmaceuticals declared audited financial results for Q4FY26 and FY26. The company recommended a final dividend of ₹0.40 per share. The Board also approved the shifting of the registered office effective May 25, 2026, and the appointment of new cost and internal auditors for FY27.
The declaration of a dividend and the approval of financial results are material events for shareholders. The office shift and auditor appointments are routine corporate actions.
The announcement includes a positive development in the form of a dividend recommendation and approval of financial results with an unmodified auditor's opinion.
SMS Pharmaceuticals Limited announced its audited financial results for the fourth quarter and full year ended March 31, 2026. The Board of Directors, in their meeting held on May 22, 2026, approved the standalone and consolidated financial results, which received an unmodified opinion from the statutory auditors.
The company recommended a final dividend of ₹0.40 (40%) per equity share of face value ₹1, subject to shareholder approval at the upcoming Annual General Meeting (AGM). The date for the AGM and book closure for dividend will be communicated later.
Additionally, the Board approved the shifting of the company's registered office within Hyderabad, from Banjara Hills to Kondapur, effective May 25, 2026. The appointments of M/s. Annapragada & Co. as Cost Auditors and M/s. Adusumilli & Associates as Internal Auditors for the financial year 2026-27 were also approved.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.